Preliminary study on pharmacokinetic of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 495-498

  Fazeny Dörner, Barbara ^a   Mader, Robert M ^a   Piribauer, Maria ^a   Rizovski, Blanka ^a   Stögermaier, Barbara ^a   Marosi, Christine ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dacarbazine; Fotemustine; Gender; Gender specific response; Pharmacokinetics

Indexed keywords

DACARBAZINE; FOTEMUSTINE; ALKYLATING AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; EVALUATION; FEMALE; GENDER; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; RANK SUM TEST; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL SIGNIFICANCE; TIME; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; SEX DIFFERENCE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SEX FACTORS;

EID: 2942612355     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2002; 344:1196-1206.
2. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12:2248-2253.
3. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.
4. Milano G, Etienne M, Pierrefite V. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79:627-630.
5. Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1992; 12:1291-1295.
6. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha StS, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20:1491-1498.
7. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995; 36:473-476.
8. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 1992; 29:391-393.
9. Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, et al. Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases. Eur J Cancer 1998; 34:87-91.
10. Iliadis A, Launay-Iliadis MC, Lucas C, Fety R, Lokiec F, Tranchand B, et al. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French Cancer Multicenter Study. Eur J Cancer 1996; 32A:455-460.
11. Tranchand B, Lucas C, Biron P, Giroux B, Gordon B, Richards R, et al. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chlorethanol in patients with high-grade gliomas. Cancer Chemother Pharmacol 1993; 32:46-52.
12. Luger SM, Kirkwood JM, Ernstoff MS. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst 1990; 82:1934-1937.
13. Cocconi G, Bella M, Calabresi F, et al. DTIC vs. DTIC plus tamoxifen in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1990; 9:1076.
14. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71:465-469.
15. Presant CA, Bartolucci AA. Prognostic factors in metastatic malignant melanoma. The Southeastern Cancer Study Group experience. Cancer 1982; 49:2192-2196.
16. Fazeny-Dörner B, Mario Veitl M, Wenzel B, Rössler K, Ungersböck K, Dieckmann K, et al. Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. Br J Cancer 2003; 88:496-501.
17. Fazeny-Dörner B, Veitl M, Rössler M, Killer M, Ungersböck K, Dieckmann K, et al. Second-line chemotherapy with dacarbacine (D) and fotemustine (F) in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 2003; 14:437-442.
18. Kleihues P, Sobin LH. World Health Organization classification of tumours. Cancer 2000; 88:2887-2993.
19. Joukhadar C, Brunner M, Mader R, Schrolnberger C, Klein N, Hertling I, McClay EF, Mastrangelo MJ, Bellet RE Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into human malignant melanoma lesions. Cancer 2001; 92:2190-2196.
20. Gordon BH, Richards RP, Hiley MP, Gray AJ, Ings RM, Campbell DB. A new method for the measurement of nitrosoureas in plasma: an h.p.l.c. procedure for the measurement of fotemustine kinetics. Xenobiotica 1989; 19:329-339.
21. NCI. Common Toxicity Criteria. Bethesda, MD: National Cancer Institute, Division of Cancer Treatment; 1988.
22. MacDonald DR, Cascino TL, Schold SC, Cairncross G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 7:1277-1280.
23. Mader RM, Steger GG, Rizovski B, Djavanmard MP, Scheithauer W, Jakesz R, et al. Stereospecific pharmacokinetics of [R,S]-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol 1995; 40:209-215.
24. Adkins DR, Irvin R, Kuhn J, Boldt DH, Roodman GD, Salzmann D, et al. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. Invest New Drugs 1993; 11:169-179.
25. Buesa JM, Urrechaga E. Clinical pharmacokinetics of high-dose DTIC. Cancer Chemother Pharmacol 1991; 28:475-479.